The Very Favorable Metastatic Renal Cell Carcinoma (mRCC) Risk Group: Data From the International Metastatic RCC Database Consortium (IMDC)

Kidney Cancer Research: Andrew Schmidt, MBBS presents a study that identifies a very favorable risk group in advanced kidney cancer patients treated with first-line therapy. ASCO #GU21 abstract 339.

Related Presenters

Andrew Lachlan Schmidt, M.B.,B.S..

Andrew Lachlan Schmidt, M.B.,B.S.

Research Fellow in Medicine


View Profile

Related Videos